A Study to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe Plaque Psoriasis

• ClinicalTrials.gov Identifier: NCT03895372
• Recruitment Status: Completed
• First Posted: March 29, 2019
• Results First Posted: August 27, 2021
• Last Update Posted: August 27, 2021
• Sponsor: Pfizer
• Information provided by (Responsible Party): Pfizer

Study Description

Brief Summary:

This multicenter study is being conducted to provide additional PF-06826647 safety and tolerability data, and to further explore the clinical efficacy of PF-06826647 in the treatment of moderate to severe plaque psoriasis. Additionally, the study is intended to enable selection of oral dose and dosing regimen for the future clinical development of PF-06826647.

Condition or disease	Intervention/treatment	Phase
Psoriasis	Drug: PF-06826647 or Placebo; Drug: PF-06826647	Phase 2

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 179 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Double (Participant, Investigator)
• Primary Purpose: Treatment
• Official Title: A PHASE 2, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-06826647 IN PARTICIPANTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS
• Actual Study Start Date: June 27, 2019
• Actual Primary Completion Date: May 21, 2020
• Actual Study Completion Date: November 26, 2020

Arms and Interventions

Arm	Intervention/treatment
Experimental: PF-06826647 Drug Dose Level 1; Delivered orally for 16 weeks during the Investigational Treatment Period	Drug: PF-06826647 or Placebo; Delivered orally (tablet) once daily (QD) for 16 weeks during the Investigational Treatment Period
Experimental: PF-06826647 Placebo; Delivered orally for 16 weeks during the Investigational Treatment Period	Drug: PF-06826647 or Placebo; Delivered orally (tablet) once daily (QD) for 16 weeks during the Investigational Treatment Period
Experimental: PF-06826647 Drug Dose Level 2; Delivered orally for 16 weeks during the Investigational Treatment Period	Drug: PF-06826647 or Placebo; Delivered orally (tablet) once daily (QD) for 16 weeks during the Investigational Treatment Period
Experimental: PF-06826647 Drug Dose Level 3; Delivered orally for 16 weeks during the Investigational Treatment Period then 24 weeks in Extension Period.	Drug: PF-06826647 or Placebo; Delivered orally (tablet) once daily (QD) for 16 weeks during the Investigational Treatment Period; Drug: PF-06826647; Delivered orally (tablet) once daily (QD) for 24 weeks during the Extension Period
Experimental: PF-06826647 Drug Dose Level 4; Delivered orally for 16 weeks then for 24 weeks in Extension Period.	Drug: PF-06826647 or Placebo; Delivered orally (tablet) once daily (QD) for 16 weeks during the Investigational Treatment Period; Drug: PF-06826647; Delivered orally (tablet) once daily (QD) for 24 weeks during the Extension Period

Outcome Measures

Primary Outcome Measures :

1. Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI 90) Response Up to Week 16 - Investigational Treatment Period [ Time Frame: Baseline up to Week 16 ]
   The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percentage of body surface area (BSA) affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 90 response was defined as at least a 90% reduction in PASI relative to baseline. The statistical analysis was for the data at Week 16.
2. Number of Participants With Treatment-Emergent Adverse Events (All-Causality), Week 16 to Week 40 - Extension Treatment Period [ Time Frame: From Week 16 to Week 40 ]
   An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious AE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. In this outcome measure, an AE was considered treatment-emergent if the event started on or after the first dosing day and time/start time but before the last dose plus the lag time.
3. Number of Participants With Treatment-Emergent Adverse Events (Treatment Related), Week 16 to Week 40 - Extension Treatment Period [ Time Frame: From Week 16 to Week 40 ]
   Treatment-related adverse event (AE) was any untoward medical occurrence attributed to study drug in a participant who received study drug. Serious AE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. In this outcome measure, an AE was considered treatment-emergent if the event started on or after the first dosing day and time/start time but before the last dose plus the lag time. Relatedness to investigational product (PF-06826647 or placebo) was assessed by the investigator (Yes/No). Participants with multiple occurrences of an AE within a category were counted once within the category.
4. Number of Participants With Laboratory Test Abnormality - Hematology (Normal Baseline), Week 16 to Week 40 - Extension Treatment Period [ Time Frame: From Week 16 to Week 40 ]
   Following hematology parameters were analyzed for laboratory examination: hemoglobin (HGB), hematocrit, erythrocytes (Ery.), reticulocytes, Ery. mean corpuscular volume, Ery. mean corpuscular HGB, Ery. mean corpuscular HGB concentration, platelets, reticulocytes/erythrocytes, leukocytes, lymphocytes/leukocytes, neutrophils/leukocytes, basophils, basophils/leukocytes, eosinophils, eosinophils/leukocytes, monocytes, monocytes/leukocytes, activated partial thromboplastin time, prothrombin time, prothrombin international (Intl.) normalized ratio, neutrophils total count, and lymphocytes total count. LLN=lower limit of normal; ULN=upper limit of normal.
5. Number of Participants With Laboratory Test Abnormality - Chemistry (Normal Baseline), Week 16 to Week 40 - Extension Treatment Period [ Time Frame: From Week 16 to Week 40 ]
   Following clinical chemistry parameters were analyzed for laboratory examination: bilirubin, direct bilirubin, indirect bilirubin, aspartate aminotransferase, alanine aminotransferase, gamma glutamyl transferase, alkaline phosphatase, protein, albumin, blood urea nitrogen, urea, creatinine, urate, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides, sodium, potassium, chloride, calcium, bicarbonate, glucose, creatine kinase, and cholesterol.
6. Number of Participants With Laboratory Test Abnormality - Urinalysis (Normal Baseline), Week 16 to Week 40 - Extension Treatment Period [ Time Frame: From Week 16 to Week 40 ]
   Following urinalysis parameters were analyzed for laboratory examination: urine pH, urine glucose, urine ketones, urine protein, urine hemoglobin, urine urobilinogen, urine bilirubin, urine nitrite, urine leukocyte esterase, urine erythrocytes, urine leukocytes, urine hyaline, and urine bacteria.
7. Number of Participants With Electrocardiogram (ECG) Data Meeting Pre-defined Criteria, Week 16 to Week 40 - Extension Treatment Period [ Time Frame: From Week 16 to Week 40 ]
   Criteria for ECG abnormalities: maximum increase PR interval increase from baseline (IFB): percent change (Pctchg) >=25 percent (%) for baseline value of >200 milliseconds (msec) and Pctchg>=50% for baseline value of <=200 msec for PR interval, a maximum IFB: Pctchg>=50%, maximum QTcF interval (Fridericia's Correction) of 450 msec to <=480 msec, 480 msec to <=500 msec and a maximum change of <30 change =<60 or >60 msec from baseline.
8. Number of Participants With Vital Sign Data Meeting Pre-defined Criteria, Week 16 to Week 40 - Extension Treatment Period [ Time Frame: From Week 16 to Week 40 ]
   The vital signs were obtained with participant in the seated position, after having sat calmly for at least 5 minutes. Criteria for vital signs abnormalities: sitting diastolic blood pressure (BP) < 50 millimeter of mercury (mmHg), sitting diastolic BP change >= 20 mmHg increase, sitting diastolic BP change >= 20 mmHg decrease, sitting systolic BP < 90 mmHg, sitting systolic BP change >= 30 mmHg increase, and sitting systolic BP change >= 30 mmHg decrease.

Secondary Outcome Measures :

1. Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI 75) Response Up to Week 16 - Investigational Treatment Period [ Time Frame: Baseline up to Week 16 ]
   The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of body surface area (BSA)" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 75 response was defined as at least a 75 percent (%) reduction in PASI relative to Baseline. The statistical analysis was for the data at Week 16.
2. Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of "Clear" or "Almost Clear" and >=2 Points Improvement Up to Week 16 - Investigational Treatment Period [ Time Frame: Baseline up to Week 16 ]
   The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). The statistical analysis was for the data at Week 16.
3. Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of "Clear" or "Almost Clear", Up to Week 16 - Investigational Treatment Period [ Time Frame: Baseline up to Week 16 ]
   The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear). The statistical analysis was for the data at Week 16.
4. Percentage of Participants With a Psoriasis Area and Severity Index 50 (PASI 50) Response Up to Week 16 - Investigational Treatment Period [ Time Frame: Baseline up to Week 16 ]
   The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and "percent of BSA" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 50 response was defined as at least 50% reduction in PASI relative to Baseline.
5. Percentage of Participants With a Psoriasis Area and Severity Index 100 (PASI 100) Response Up to Week 16 - Investigational Treatment Period [ Time Frame: Baseline up to Week 16 ]
   The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of body surface area (BSA)" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 100 response was defined as at least a 100 percent (%) reduction in PASI relative to Baseline.
6. Change From Baseline in Psoriasis Area and Severity Index (PASI) Scores, Up to Week 16 - Investigational Treatment Period [ Time Frame: Baseline up to Week 16 ]
   Combined assessment of lesion severity and area affected into single score. Body was divided into 4 sections: head, arms, trunk, legs. For each section, percent area of skin involved was estimated: 0= 0% to 6= 90-100%. Severity was estimated by clinical signs: erythema, induration, desquamation; scale: 0= none to 4= maximum. Final PASI = sum of severity parameters for each section*area score*weight of section (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4); total possible score range: 0= no disease to 72= maximal disease. The statistical analysis was for the data at Week 16.
7. Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Scores, Up to Week 16 - Investigational Treatment Period [ Time Frame: Baseline up to Week 16 ]
   Combined assessment of lesion severity and area affected into single score. Body was divided into 4 sections: head, arms, trunk, legs. For each section, percent area of skin involved was estimated: 0= 0% to 6= 90-100%. Severity was estimated by clinical signs: erythema, induration, desquamation; scale: 0= none to 4= maximum. Final PASI = sum of severity parameters for each section*area score*weight of section (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4); total possible score range: 0= no disease to 72= maximal disease. The statistical analysis was for the data at Week 16.
8. Change From Baseline in Peak-Pruritus Numerical Rating Scale (PP-NRS) Scores, Up to Week 16 - Investigational Treatment Period [ Time Frame: Baseline up to Week 16 ]
   The intensity of pruritus was assessed by a PP-NRS, an 11-category numeric rating scale from 0 to 10, which was participant reported. Participants were asked to assess their itch over the past 24 hours, anchored by the terms "no itch" (0) and "worst itch imaginable" (10) at the ends. The statistical analysis was for the data at Week 16.
9. Percentage of Participants Achieving Psoriasis Symptom Inventory (PSI) Response of "Not at All" or "Mild" on Every Item, Up to Week 16 - Investigational Treatment Period [ Time Frame: Baseline up to Week 16 ]
   The Psoriasis Symptom Inventory (PSI) is a self administered 8-item questionnaire that measures the severity of psoriasis symptoms over the past 24 hours and the past 7 days. The measure includes concepts of itch, pain, burning, stinging, cracking, scaling, flaking, and redness. Participants were asked to respond to each item using a 5-point Likert response scale: 0: not all severe, 1: mild, 2: moderate, 3: severe and 4: very severe. The statistical analysis was for the data at Week 16.
10. Change From Baseline in Psoriasis Symptom Inventory (PSI) Up to Week 16 - Investigational Treatment Period [ Time Frame: Baseline up to Week 16 ]
    The Psoriasis Symptom Inventory (PSI) is a self administered 8-item questionnaire that measures the severity of psoriasis symptoms over the past 24 hours and the past 7 days. The measure includes concepts of itch, pain, burning, stinging, cracking, scaling, flaking, and redness. Participants were asked to respond to each item using a 5-point Likert response scale: 0: not all severe, 1: mild, 2: moderate, 3: severe and 4: very severe. The outcome of PSI is the sum of the scores for the 8 items. The total score range of PSI is 0-32. A negative change from baseline means a better outcome and the bigger score decrease means a better outcome. The statistical analysis was for the data at Week 16.
11. Number of Participants With Treatment-Emergent Adverse Events (All-Causality), Up to Week 16 - Investigational Treatment Period [ Time Frame: Baseline up to Week 16 ]
    An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious AE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. In this outcome measure, an AE was considered treatment-emergent if the event started on or after the first dosing day and time/start time but before the last dose plus the lag time.
12. Number of Participants With Treatment-Emergent Adverse Events (Treatment Related), Up to Week 16 - Investigational Treatment Period [ Time Frame: Baseline up to Week 16 ]
    Treatment-related adverse event (AE) was any untoward medical occurrence attributed to study drug in a participant who received study drug ((PF-06826647 or placebo). Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. In this outcome measure, an AE was considered treatment-emergent if the event started on or after the first dosing day and time/start time but before the last dose plus the lag time. Relatedness to investigational product (PF-06826647 or placebo) was assessed by the investigator (Yes/No). Participants with multiple occurrences of an AE within a category were counted once within the category.
13. Number of Participants With Electrocardiogram (ECG) Data Meeting Pre-defined Criteria, Up to Week 16 - Investigational Treatment Period [ Time Frame: Baseline up to Week 16 ]
    Criteria for ECG abnormalities: Criteria for ECG abnormalities: maximum PR interval >=300 milliseconds (msec) and maximum increase PR interval increase from baseline (IFB): percent change (Pctchg) >=25 percent (%) for baseline value of >200 msec and Pctchg>=50% for baseline value of <=200 msec for PR interval, maximum QRS interval >=140 msec and a maximum IFB: Pctchg>=50%, maximum QTcF interval (Fridericia's Correction) of 450 msec to <=480 msec, 480 msec to <=500 msec and a maximum change of <30change<=60 or >60 msec from baseline.
14. Number of Participants With Vital Sign Data Meeting Pre-defined Criteria, Up to Week 16 - Investigational Treatment Period [ Time Frame: Baseline up to Week 16 ]
    The vital signs were obtained with participant in the seated position, after having sat calmly for at least 5 minutes. Criteria for vital signs abnormalities: pulse rate >120 beats per minute (BPM), sitting diastolic blood pressure (BP) change >=20 millimeter of mercury (mmHg) increase, sitting diastolic BP change >=20 mmHg decrease, sitting systolic BP <90 mmHg, sitting systolic BP change >=30 mmHg increase, and sitting systolic BP change >=30 mmHg decrease.
15. Number of Participants With Laboratory Test Abnormality - Hematology (Normal Baseline), Up to Week 16 - Investigational Treatment Period [ Time Frame: Baseline up to Week 16 ]
    Following hematology parameters were analyzed for laboratory examination: hemoglobin (HGB), hematocrit, erythrocytes (Ery.), reticulocytes, Ery. mean corpuscular volume, Ery. mean corpuscular HGB, Ery. mean corpuscular HGB concentration, platelets, reticulocytes/erythrocytes, leukocytes, lymphocytes/leukocytes, neutrophils/leukocytes, basophils, basophils/leukocytes, eosinophils, eosinophils/leukocytes, monocytes, monocytes/leukocytes, activated partial thromboplastin time, prothrombin time, neutrophils total count, and lymphocytes total count. LLN=lower limit of normal; ULN=upper limit of normal.
16. Number of Participants With Laboratory Test Abnormality - Chemistry (Normal Baseline), Up to Week 16 - Investigational Treatment Period [ Time Frame: Baseline up to Week 16. ]
    Following clinical chemistry parameters were analyzed for laboratory examination: bilirubin, indirect bilirubin, aspartate aminotransferase, alanine aminotransferase, gamma glutamyl transferase, alkaline phosphatase, protein, albumin, blood urea nitrogen, urea, creatinine, urate, high-density lipoprotein (HDL) cholesterol, triglycerides, sodium, potassium, chloride, calcium, bicarbonate, glucose, creatine kinase, and cholesterol. LLN=lower limit of normal; ULN=upper limit of normal.
17. Number of Participants With Laboratory Test Abnormality - Urinalysis (Normal Baseline), Up to Week 16 - Investigational Treatment Period [ Time Frame: Baseline up to Week 16 ]
    Following urinalysis parameters were analyzed for laboratory examination: urine pH, urine glucose, urine ketones, urine protein, urine hemoglobin, urine urobilinogen, urine bilirubin, urine nitrite, urine leukocyte esterase, urine erythrocytes, urine leukocytes, urine hyaline, and urine bacteria.

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 75 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Male or female between the ages of 18 and 75 years.
• Participants with a diagnosis of plaque psoriasis (psoriasis vulgaris) for at least 6 months.
• Have a PASI score of 12 or greater AND a Physician Global Assessment score of 3 (moderate) or 4 (severe).
• Have plaque-type psoriasis covering at least 10 % of total body surface area (BSA).

Exclusion Criteria:

• Have non-plaque forms of psoriasis.
• Drug-induced psoriasis.
• Current active infection.
• Infected with Mycobacterium tuberculosis (TB).
• Have any history of malignancies.
• Require treatment with prohibited concomitant medications(s).
• Positive for hepatitis B or C, or human immunodeficiency virus (HIV).

Contacts and Locations

Locations

United States, Arizona

Alliance Dermatology and Mohs Center

Phoenix, Arizona, United States, 85032

Center for Dermatology and Plastic Surgery/CCT

Scottsdale, Arizona, United States, 85260

Center for Dermatology and Plastic Surgery

Scottsdale, Arizona, United States, 85260

United States, California

Anaheim Clinical Trials, LLC

Anaheim, California, United States, 92801

Kern Research. Inc.

Bakersfield, California, United States, 93301

California Dermatology & Clinical Research Institute

Encinitas, California, United States, 92024

Imaging Healthcare Specialists

San Diego, California, United States, 92103

Medderm Associates Dermatology

San Diego, California, United States, 92103

University Clinical Trials

San Diego, California, United States, 92123

United States, Florida

Renstar Medical Research

Ocala, Florida, United States, 34470

MidState Skin Institute

Ocala, Florida, United States, 34471

Renstar Medical Research

Ocala, Florida, United States, 34471

Advanced Diagnostic Group

Orange Park, Florida, United States, 32073

Park Avenue Dermatology

Orange Park, Florida, United States, 32073

Leavitt Medical Associates of Florida d/b/a Ameriderm Research

Ormond Beach, Florida, United States, 32174

ForCare Clinical Research

Tampa, Florida, United States, 33613

United States, Georgia

Hamilton Research, LLC

Alpharetta, Georgia, United States, 30022

United States, Kansas

Epiphany Dermatology of Kansas, LLC

Overland Park, Kansas, United States, 66215

United States, Kentucky

Qualmedica Research, LLC

Owensboro, Kentucky, United States, 42301

Owensboro Dermatology Associates

Owensboro, Kentucky, United States, 42303

United States, Louisiana

DelRicht Research

Baton Rouge, Louisiana, United States, 70809

DelRicht Research

Baton Rouge, Louisiana, United States, 70816

United States, Oklahoma

Vital Prospects Clinical Research Institute, PC

Tulsa, Oklahoma, United States, 74136

United States, Texas

Arlington Research Center, Inc.

Arlington, Texas, United States, 76011

Canada, Manitoba

Wiseman Dermatology Research Inc.

Winnipeg, Manitoba, Canada, R3M 3Z4

Canada, Ontario

SKiN Health

Cobourg, Ontario, Canada, K9A 0Z4

Dermatrials Research

Hamilton, Ontario, Canada, L8N 1Y2

Lynderm Research Inc.

Markham, Ontario, Canada, L3P 1X3

Toronto Research Centre

Toronto, Ontario, Canada, M3H 5Y8

K. Papp Clinical Research

Waterloo, Ontario, Canada, N2J 1C4

Canada, Quebec

Centre Radiologique de l'Estrie

Sherbrooke, Quebec, Canada, J1L 0H8

Diex Recherche Sherbrooke Inc.

Sherbrooke, Quebec, Canada, J1L 0H8

Japan

Nagoya City University Hospital

Nagoya, Aichi, Japan, 467-8602

Teikyo University Hospital

Itabashi-ku, Tokyo, Japan, 173-8606

NTT Medical Center Tokyo

Shinagawa-ku, Tokyo, Japan, 141-8625

Seibo International Catholic Hospital

Shinjuku-ku, Tokyo, Japan, 161-8521

Fukuoka University Hospital

Fukuoka, Japan, 814-0180

Tokyo Medical University Hospital

Tokyo, Japan, 160-0023

Poland

Malopolskie Centrum Medyczn

Krakow, Malopolskie, Poland, 30-510

MTZ Clinical Research Sp. z o.o.

Warszawa, Mazowieckie, Poland, 02-106

Zdrowie Osteo-Medic s.c. L. i A. Racewicz, A. i J. Supronik

Bialystok, Podlaskie, Poland, 15-351

SpecDerm Poznanska Sp. J.

Bialystok, Poland, 15-375

Prywatny Gabinet Dermatologiczny Elzbieta Klujszo

Kielce, Poland, 25-316

Pratia MCM Krakow

Krakow, Poland, 30-510

Tomasz Blicharski Lubelskie Centrum Diagnostyczne

Swidnik, Lubelskie, Poland, 21-040

Sponsors and Collaborators

Pfizer

Investigators

• Study Director: Pfizer CT.gov Call Center; Pfizer

  Study Documents (Full-Text)

Documents provided by Pfizer:

Study Protocol  [PDF] October 1, 2019

Statistical Analysis Plan  [PDF] November 29, 2020

More Information

Additional Information:

To obtain contact information for a study center near you, click here. 

• Responsible Party: Pfizer
• ClinicalTrials.gov Identifier: NCT03895372
• Other Study ID Numbers: C2501004; 2018-004669-16 ( EudraCT Number )
• First Posted: March 29, 2019
• Results First Posted: August 27, 2021
• Last Update Posted: August 27, 2021
• Last Verified: August 2021

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No
• Plan Description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Psoriasis; Skin Diseases, Papulosquamous; Skin Diseases